Keywords
Prostate cancer
Indications
Treatment program
Submitted : 2024-06-18
Accepted : 2024-07-03
Published : 2024-07-18
Abstract
Prostate cancer is a common malignant tumor of the urinary system in men, and the incidence and detection rate of prostate cancer have been rising significantly in recent years. Androgens play an important role in the occurrence and development of prostate cancer, so hormone deprivation therapy has become an essential means of prostate cancer treatment. Abiraterone acetate is a therapeutic agent for prostate cancer by inhibiting the enzyme activity of CYP17, thereby blocking androgen biosynthesis. In this paper, we present a review of the current mechanism of action of abiraterone acetate for prostate cancer treatment, research progress, and its side effects and limitations. It is expected to provide help for further research on the treatment of prostate cancer.
References
Ma D, An H, Wang Y, 2023, Progress of a Real-World Study of Abiraterone Acetate Versus Docetaxel in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer. Oncology Control Research, 50(05): 538–543.
Sung H, Ferlay J, Siegel RL, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209–249.
Hu H, Zhuo D, Zhang Z, et al., 2024, The Value of PI-RADS v2.1 Combined with PSAMR in the Diagnosis of Prostate Cancer with tPSA < 20 ng/mL. Journal of Clinical Urology, 39(02): 125–130.
Sheng XN, 2023, Review of Current Status and Progress of Synergistic Inhibition of the Androgen Receptor and PARP as a New Therapeutic Modality for Prostate Cancer. Journal of Urology (Electronic Edition), 15(03): 10–17.
Zhang J, Liu S, 2023, Effects of Abiraterone Acetate Combined with Docetaxel on Serum Indices and Survival in Patients with Castration-Resistant Prostate Cancer. Huaihai Medicine, 41(04): 404–406.
Wang L, Huo B, Liu Q, et al., 2019, Clinical Efficacy Observation of Apatinib Mesylate Targeted Therapy for Metastatic Castration-Resistant Prostate Cancer. China Tumor Clinic, 46(16): 845–850.
Yin B, Lu W, 2020, Correlation of Serum Prostate-Specific Antigen, Testosterone, and Distant Metastasis After Prostate Cancer Surgery. Experimental and Laboratory Medicine, 38(03): 556–558.
Li ZQ, Liu YB, 2019, Analysis of the Diagnostic Effect of Prostate-Specific Antigen Combined with Testosterone in Detecting Bone Metastasis of Prostate Cancer. Chinese Drugs and Clinics, 19(06): 945–946.
Liu M, Yan Q, Zhou D, 2017, Pharmacologic Effects of Abiraterone and Clinical Research Progress. Chinese Journal of New Drugs and Clinics, 36(02): 65–70.
Zong H, Chen Z, Tang L, et al., 2022, Effect of Abiraterone Acetate on Chemosensitivity of Goserelin Depot-Resistant Prostate Cancer Cells. Chinese Journal of Clinical Pharmacology, 38(05): 399–403.